Compare Stocks

bpost NV/SA, together with its subsidiaries, provides mail and parcel services to individuals, businesses, and public institutions in Belgium, rest of Europe, the United States, and internationally. It operates through Belgium, E-Logistics Eurasia, and E-Logistics North America segments. The company offers collection, transport, sorting, and distribution of addressed and non-addressed mail, printed documents, newspapers, periodicals, and parcels, as well as banking and financial products, e-commerce logistics, express delivery, and related services. It also provides transactional mails, advertising mails, press, domestic and international parcels, and logistic solutions; e-commerce fulfilment, including warehousing and handling of goods; e-commerce cross-border services, including custom duties services; operational back-office services, including call center, payment and financial, fraud and tax, administrative and document management services; and proximity and convenience services, such as the access to the network and over-the-counter service for different partners and sale of self-produced goods, as well as retail products and goods of partners, including bpost bank products; repair of electronics; and import services. The company was founded in 1830 and is headquartered in Brussels, Belgium.

Jungheinrich Aktiengesellschaft, through its subsidiaries, provides products and solutions in the fields of material handling equipment, automated systems, digital solutions, and matching services worldwide. It operates in two segments, Intralogistics and Financial Services. The Intralogistics segment develops, produces, sells, and rents new material handling equipment and warehousing equipment products; sells and leases used trucks; and provides spare parts, as well as maintenance and repair services. The Financial Services segment engages in the sales financing and usage transfer of material handling and warehousing equipment products. The company's products portfolio includes electric and hand pallet trucks, electric pallet stackers, order pickers, reach trucks, very narrow aisle trucks; electric, diesel, and gas/LPG forklift trucks; tow tractors, trailers, and shuttles. It also offers rental of fleet, and battery and charger; contract and event hire; automated vehicles, conveyor technology, and stacker cranes; lithium-ion and lead-acid batteries; charging technology; powertrain solutions; electric drives/drivetrains; controllers; electromechanics components/control pedals/displays; electric mounting panels; and cable sets. In addition, it provides digital solutions, which include fleet management systems, as well as EasyAccess, a fleet management product to control access of forklift without a universal key; and develops software solutions. The company distributes its products through its direct sales and service network, as well as through dealers. Jungheinrich Aktiengesellschaft was founded in 1953 and is headquartered in Hamburg, Germany.

Nihon Kohden Corporation engages in development, manufacturing, sale, maintenance, and consultation of medical electronic equipment, and related systems and products in Japan, Americas, Europe, rest of Asia, and internationally. It offers physiological measuring equipment comprising electrocardiographs, electroencephalographs, and polygraphs for Cath-labs; patient monitoring systems, such as beside and central monitors; and treatment equipment including defibrillators, automated external defibrillators, ventilators, and pacemakers. The company also provides medical support system, which includes diagnostic and clinical information system; and in-vitro diagnostic equipment comprising hematology and clinical chemistry analyzers. In addition, it operates insurance brokerage and technology licensing business. The company was incorporated in 1951 and is headquartered in Shinjuku, Japan.

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, France, rest of EU, the United States, and internationally. The company operates through Oncology and RNA interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca for treating patients with small cell lung cancer. The company also develops PM14, which is in phase II clinical trials for the treatment of solid tumors, as well as in Phase I clinical trial for the treatment of soft tissue sarcoma and prostate cancer; PM534 that is Phase I clinical trial for treating solid tumors; Tivanisiran, which is in Phase III clinical trial for the treatment of dry eye disease; and SYL1801 that is in phase II clinical trial for treating macular degeneration. In addition, it engages in the development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. The company was incorporated in 1986 and is based in Madrid, Spain.